Gamma Variant RBD-based ARVAC-CG vaccine / National University of San Martin, National Scientific and Technical Research Council, Pablo Cassara - LARVOL DELTA

COVID-19 vaccine production and the technological gap in the Global South: The cases of Argentina and Brazil. (PubMed, Vaccine) - "Concurrently, Argentina launched the ARVAC Cecilia Grierson vaccine through a public-private partnership. The persistent technological gap has resulted in continued dependence on foreign imports, undermining their capacity to compete effectively in the international vaccine market. Despite notable achievements in vaccine development and production, the experiences of Argentina and Brazil exemplify the structural difficulties faced by stagnant middle-income nations in achieving vaccine self-sufficiency and technological sovereignty in pharmaceutical manufacturing."

Journal • Infectious Disease • Novel Coronavirus Disease

ARVAC-F2/3-002: ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine (clinicaltrials.gov) - P2/3 | N=2014 | Completed | Sponsor: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine (clinicaltrials.gov) - P1 | N=80 | Completed | Sponsor: Laboratorio Pablo Cassara S.R.L. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

ARVAC-F2/3-002: ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine (clinicaltrials.gov) - P2/3 | N=2014 | Active, not recruiting | Sponsor: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: Laboratorio Pablo Cassara S.R.L. | Trial completion date: Jun 2023 ➔ Oct 2023

Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IFNG

ARVAC-F2/3-002: ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) (clinicaltrials.gov) - P2/3 | N=2014 | Recruiting | Sponsor: Mónica Edith Lombardo

New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine (clinicaltrials.gov) - P1 | N=80 | Active, not recruiting | Sponsor: Laboratorio Pablo Cassara S.R.L.

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IFNG

COVID-19 vaccination certificates and lifting public health and social measures: ethical considerations. (PubMed, East Mediterr Health J) - "Vaccination certificates may undermine a population-based approach to COVID-19 vaccination to achieve and accelerate universal lifting of PHSMs, result in unfair and inequitable health and social outcomes, and generate social divisions at a time when solidarity within (and between) countries is necessary to navigate the pandemic and its burdens. Further research on the ethical acceptability and impact of COVID-19 vaccine certificates in countries that have implemented them should be carried out to inform future ethical considerations on this issue."

Journal • Infectious Disease • Novel Coronavirus Disease